drugset / Trial / NCT04258943

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

NCT04258943

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML), to preliminary estimate the safety and tolerability and efficacy, and to evaluate the PK of bosutinib in this patient population.

Timeline

Start
2020-07-06
Primary completion
2028-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule 300 mg/m2 Oral
Subject Bosutinib Small molecule 350 mg/m2 Oral
Subject Bosutinib Small molecule 400 mg/m2 Oral